CN104997783A - 端粒酶阳性细胞中端粒长度的调节和癌症治疗 - Google Patents

端粒酶阳性细胞中端粒长度的调节和癌症治疗 Download PDF

Info

Publication number
CN104997783A
CN104997783A CN201510092529.5A CN201510092529A CN104997783A CN 104997783 A CN104997783 A CN 104997783A CN 201510092529 A CN201510092529 A CN 201510092529A CN 104997783 A CN104997783 A CN 104997783A
Authority
CN
China
Prior art keywords
cancer
cell
purposes
carcinoma
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510092529.5A
Other languages
English (en)
Chinese (zh)
Inventor
I·E·博恩达尔耶夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALT solutions Inc
Original Assignee
ALT solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALT solutions Inc filed Critical ALT solutions Inc
Publication of CN104997783A publication Critical patent/CN104997783A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201510092529.5A 2005-03-25 2006-03-27 端粒酶阳性细胞中端粒长度的调节和癌症治疗 Pending CN104997783A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66510505P 2005-03-25 2005-03-25
US60/665,105 2005-03-25
CNA200680015221XA CN101193643A (zh) 2005-03-25 2006-03-27 端粒酶阳性细胞中端粒长度的调节和癌症治疗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA200680015221XA Division CN101193643A (zh) 2005-03-25 2006-03-27 端粒酶阳性细胞中端粒长度的调节和癌症治疗

Publications (1)

Publication Number Publication Date
CN104997783A true CN104997783A (zh) 2015-10-28

Family

ID=37053967

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510092529.5A Pending CN104997783A (zh) 2005-03-25 2006-03-27 端粒酶阳性细胞中端粒长度的调节和癌症治疗
CNA200680015221XA Pending CN101193643A (zh) 2005-03-25 2006-03-27 端粒酶阳性细胞中端粒长度的调节和癌症治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA200680015221XA Pending CN101193643A (zh) 2005-03-25 2006-03-27 端粒酶阳性细胞中端粒长度的调节和癌症治疗

Country Status (6)

Country Link
US (5) US7741296B2 (https=)
EP (1) EP1868615A4 (https=)
JP (2) JP2008536822A (https=)
CN (2) CN104997783A (https=)
CA (1) CA2602562C (https=)
WO (1) WO2006104975A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112168829A (zh) * 2020-09-24 2021-01-05 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
CN101588805A (zh) * 2005-05-18 2009-11-25 Alt解决方案公司 为预防和治疗癌症对癌细胞中端粒长度的药理学调节
WO2007106561A2 (en) * 2006-03-14 2007-09-20 Alt Solutions, Inc. Prevention and treatment of cancer and other diseases
ES2874774T3 (es) 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
CN102660650A (zh) * 2012-05-25 2012-09-12 云南路易斯中药现代化工程技术研究中心 一种实时定量pcr测量样品中染色体端粒平均长度的绝对值的试剂盒及应用
CA2892445C (en) * 2012-11-30 2022-06-28 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9795242B2 (en) 2013-02-14 2017-10-24 Cirkul, Inc. Additive delivery systems and containers
US10888826B2 (en) 2014-11-21 2021-01-12 Cirkul, Inc. Adjustable additive cartridge systems and methods
JP6730298B2 (ja) 2014-11-21 2020-07-29 サークル, インコーポレイテッド.Cirkul, Inc. 添加剤カートリッジ及び添加剤供給システム
EP3753563A1 (en) * 2019-06-20 2020-12-23 Helmholtz-Zentrum für Infektionsforschung GmbH Anti-herpesvirus guanosine analogue for the inhibition of basal autophagy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US5489508A (en) * 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
WO1997021452A2 (en) * 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
ATE462447T1 (de) * 1999-06-23 2010-04-15 Univ Vermont Verfahren und mittels zur manipulierung der expression des uncoupling proteins
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112168829A (zh) * 2020-09-24 2021-01-05 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Also Published As

Publication number Publication date
US20140065072A1 (en) 2014-03-06
US8580753B2 (en) 2013-11-12
US20160000937A1 (en) 2016-01-07
CA2602562A1 (en) 2006-10-05
US7741296B2 (en) 2010-06-22
JP2008536822A (ja) 2008-09-11
US8097595B2 (en) 2012-01-17
EP1868615A4 (en) 2012-06-27
CN101193643A (zh) 2008-06-04
US20120107863A1 (en) 2012-05-03
WO2006104975A3 (en) 2007-12-27
JP2013224953A (ja) 2013-10-31
US20100227832A1 (en) 2010-09-09
US20090023677A1 (en) 2009-01-22
CA2602562C (en) 2015-07-07
WO2006104975A2 (en) 2006-10-05
EP1868615A2 (en) 2007-12-26

Similar Documents

Publication Publication Date Title
US8580753B2 (en) Modulation of telomere length in telomerase positive cells and cancer therapy
US9078901B2 (en) Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
Röth et al. Imetelstat (GRN163L)-telomerase-based cancer therapy
Mender et al. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2′-deoxyguanosine
KR102294819B1 (ko) 골증식성 장애 및 골증식성 신생물의 치료를 위한 텔로메라제 저해제들의 용도
EP2623105A2 (en) Modulation of line-1 reverse transcriptase
JP5571947B2 (ja) 癌およびその他の疾患の予防および治療
AU766084B2 (en) Modulation of gene expression by combination therapy
CN101443021A (zh) 癌和其他疾病的预防和治疗
Xiong et al. In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir)
Leeansyah et al. Inhibition of telomerase activity by HIV Nucleos (t) ide Reverse Transcriptase Inhibitors: a potential factor contributing to HIV-associated accelerated ageing
Iwazaki et al. 2′-Deoxycytidine decreases the anti-tumor effects of 5-fluorouracil on mouse myeloma cells
Chen et al. Methods for modulation and inhibition of telomerase
Requena Torres et al. The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine
Tamakawa Combination chemotherapy with telomerase inhibitors and genotoxic compounds against breast and colorectal cancers
Gryaznov Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2′-Deoxyguanosine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151028